aciclovir sun 200 mg tablett
sun pharmaceutical industries europe b.v. - aciklovir - tablett - 200 mg - aciklovir 200 mg aktiv substans - aciklovir
aciclovir sun 400 mg tablett
sun pharmaceutical industries europe b.v. - aciklovir - tablett - 400 mg - aciklovir 400 mg aktiv substans - aciklovir
aciclovir sun 800 mg tablett
sun pharmaceutical industries europe b.v. - aciklovir - tablett - 800 mg - aciklovir 800 mg aktiv substans - aciklovir
lansoprazol sun 15 mg munsönderfallande tablett
sun pharmaceutical industries europe b.v. - lansoprazol - munsönderfallande tablett - 15 mg - sackaros hjälpämne; mannitol hjälpämne; natriumlaurilsulfat hjälpämne; lansoprazol 15 mg aktiv substans - lansoprazol
lansoprazol sun 30 mg munsönderfallande tablett
sun pharmaceutical industries europe b.v. - lansoprazol - munsönderfallande tablett - 30 mg - sackaros hjälpämne; mannitol hjälpämne; natriumlaurilsulfat hjälpämne; lansoprazol 30 mg aktiv substans - lansoprazol
oktreotid sun 100 mikrogram/ml injektionsvätska, lösning
sun pharmaceutical industries europe b.v. - oktreotidacetat - injektionsvätska, lösning - 100 mikrogram/ml - oktreotidacetat - mikrog aktiv substans - oktreotid
oktreotid sun 200 mikrogram/ml injektionsvätska, lösning
sun pharmaceutical industries europe b.v. - oktreotidacetat - injektionsvätska, lösning - 200 mikrogram/ml - oktreotidacetat - mikrog aktiv substans - oktreotid
oktreotid sun 50 mikrogram/ml injektionsvätska, lösning
sun pharmaceutical industries europe b.v. - oktreotidacetat - injektionsvätska, lösning - 50 mikrogram/ml - oktreotidacetat aktiv substans - oktreotid
oktreotid sun 500 mikrogram/ml injektionsvätska, lösning
sun pharmaceutical industries europe b.v. - oktreotidacetat - injektionsvätska, lösning - 500 mikrogram/ml - oktreotidacetat - mikrog aktiv substans - oktreotid
fingolimod mylan
mylan ireland limited - fingolimod hydroklorid - multipel skleros, skovvis förlöpande - immunsuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 och 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.